Oct 23, 2026 03:02PM
Oct 16, 2026 07:00AM
Oct 16, 2026 07:00AM
Sep 29, 2026 08:00AM
Aug 16, 2026 08:05AM
Aug 5, 2026 10:40AM
Jun 17, 2026 07:00AM UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
Apr 17, 2026 02:00PM
Apr 17, 2026 02:00PM
Apr 15, 2026 07:00AM
Mar 24, 2026 02:46PM
Dec 8, 2025 07:00AM
Dec 8, 2025 07:00AM
Nov 3, 2025 04:00PM UCB gains FDA approval for first TK2 deficiency treatment KYGEVVI
Nov 3, 2025 04:00PM
Nov 3, 2025 04:00PM
Oct 29, 2025 07:00AM
Sep 17, 2025 07:00AM
Jun 12, 2025 12:30PM
May 19, 2025 12:30PM
Apr 3, 2025 07:00AM UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
Mar 19, 2025 07:00AM
Mar 12, 2025 01:54PM
Mar 7, 2025 08:00AM
Feb 27, 2025 07:00AM
Jan 16, 2025 07:00AM
Dec 6, 2024 12:00PM
Nov 26, 2024 07:00AM UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
Nov 20, 2024 07:00AM
Nov 14, 2024 12:46PM
Sep 23, 2024 07:00AM
Aug 16, 2024 05:36AM
Jun 24, 2024 07:00AM
Jun 20, 2024 08:00AM
May 23, 2024 07:00AM UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
Apr 12, 2024 07:00AM
Apr 4, 2024 07:00AM
Feb 28, 2024 07:03AM
Jan 3, 2024 07:00AM
Dec 8, 2023 02:30PM
Dec 2, 2023 07:00AM
Dec 1, 2023 07:00AM UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
Nov 14, 2023 07:00AM
Nov 1, 2023 07:00AM
Oct 31, 2023 07:00AM
Oct 18, 2023 07:00AM
Oct 17, 2023 06:34PM
Oct 13, 2023 12:00PM
Oct 12, 2023 12:20PM Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
Oct 4, 2023 01:06PM

335,390 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All